Global Velcade Market Size, Share, and Trends Analysis Report, By Application (Multiple Myeloma, and Mantle Cell Lymphoma), By Distribution Channel (Hospital Pharmacies, and Retail Drug Stores), Forecast (2022-2028)

The global velcade market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Velcade is an anti-cancer drug, also called bortezomib, used for the treatment of a plasma cell cancer called multiple myeloma and mantle cell lymphoma. The major factor attributing to the growth of the global velcade market includes the rising prevalence of multiple myeloma. According to the American Cancer Society (ACS), around 34,920 new cases of multiple myeloma were diagnosed in the US alone in 2021. Among these, around 19,320 were men and 15,600 were women. The estimated mortality due to multiple myeloma was around 12,410 in the US in 2021. Multiple myeloma is a relatively uncommon cancer occurring in one in every 132 people in the US representing around 0.76% of all cancer cases.

In addition, the increasing cases of mantle cell lymphoma are also boosting the demand for velcade for its treatment. According to the National Organization For Rare Disorders (NORD), mental cell lymphoma is a type of non-Hodgkin’s lymphoma counting for around 5% to 7% of all cases of non-Hodgkin’s lymphoma. The prevalence of mantle cell lymphoma is around 1 in every 2,00,000 people. This disease primarily affects adults. Thus, contributing to the growth of the global velcade market.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in March 2020, Karyopharm Therapeutics announced the positive top-line result of their phase-3 Boston study of the combination of XPOVIO (Selinexor), Velcade, and Dexamethasone in patients with multiple myeloma. The results from the study show that patients given this combination of drugs are found to live with 47% more without worsening the disease. Karyopharma also announced that they are going to submit the combination drug for FDA approval. Similarly, in January 2022, the UK National Institute of Health and Care Excellence (NICE) recommended the use of DVTd combination drugs for the treatment of adults with multiple myeloma. DVTd is a combination drug developed by Janssen Pharmaceutical Co. of Johnson & Johnson Pvt. Ltd. and is a combination of darzalex, velcade, thalidomide, and dexamethasone.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Johnson & Johnson Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Luoxin Pharmaceutical Group Co. Ltd., and Viatris Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Velcade  Market Report by Segment

By Application

• Multiple Myeloma
• Mantle Cell Lymphoma

By Distribution Channel

• Hospital Pharmacies
• Retail Drug Stores

Global Velcade  Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa